読み込み中
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
前日終値
$6.68
+$0.72 · +12.08%
日中の時刻はETです。市場データは遅延する場合があります。
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
日中レンジ
現在 $6.68
52週レンジ
現在 $6.68
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
43
適正価値
センチメント
53
まちまち
リスク
70
高リスク
モメンタム
31
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
日中レンジ
現在 $6.68
52週レンジ
現在 $6.68
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 347.2万 USD | 579.8万 USD | 646.6万 USD | 881.1万 USD | 959.1万 USD |
| 販売・一般管理 | 895万 USD | 856.6万 USD | 711万 USD | 1244.6万 USD | 4792.4万 USD |
| 営業費用 | 1242.2万 USD | 1436.4万 USD | 1357.6万 USD | 2125.7万 USD | 5751.5万 USD |
| 受取利息 | 12.3万 USD | 40.2万 USD | 78万 USD | 29.2万 USD | 3.8万 USD |
| 支払利息 | 12.7万 USD | — | 21.3万 USD | 8000 USD | 71.8万 USD |
| 減価償却費と償却費 | — | — | 1357.6万 USD | — | — |
| 営業利益 | −1242.2万 USD | −1436.4万 USD | −1357.6万 USD | −2125.7万 USD | −5751.5万 USD |
| 純利益 | −2835.4万 USD | −1316.2万 USD | −759.7万 USD | −2088.4万 USD | −5801.3万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2026年9月8日 | 1:25 | — | — |
株式分割 | 2024年2月5日 | 1:30 | — | — |
株式分割 | 2021年2月11日 | 1:17 | — | — |
株式分割 | 2017年8月21日 | 1:300 | — | — |
株式分割 | 2015年12月15日 | 1:250 | — | — |
株式分割 | 1998年10月21日 | 1:5 | — | — |
発効済み 2026年9月8日
1:25
発効済み 2024年2月5日
1:30
発効済み 2021年2月11日
1:17
発効済み 2017年8月21日
1:300
発効済み 2015年12月15日
1:250
発効済み 1998年10月21日
1:5
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
